Velvet Therapeutics Overview
- Year Founded
-
2013
- Status
-
Private
- Employees
-
3
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$500K
- Investors
-
3
Velvet Therapeutics General Information
Description
Developer of gene therapies intended to treat rare cancers and autoimmune diseases using a proprietary platform. The company's gene therapies are a result of research, development, and commercialization of supercoiled DNA minicircles for the transfer of DNA into primary and stem cells, enabling researchers to get better transfection efficiencies and long-term effects and also that are easily delivered for safer, effective gene and cell therapies.
Contact Information
Website
velvettherapeutics.comCorporate Office
- 2710 Reed Road
- Suite 160
- Houston, TX 77051
- United States
Corporate Office
- 2710 Reed Road
- Suite 160
- Houston, TX 77051
- United States
Velvet Therapeutics Timeline
Velvet Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Later Stage VC | 28-Aug-2023 | $500K | 00.000 | Completed | Pre-Clinical Trials | |
| 1. Seed Round | 11-Jan-2021 | 00.000 | 00.000 | 00.000 | Completed | Pre-Clinical Trials |
Velvet Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed | 0,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Velvet Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Velvet Therapeutics Patents
Velvet Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3211307-A1 | Utrapure minivectors for gene therapy | Pending | 08-Sep-2022 | 000000000 | |
| EP-4335924-A1 | Ultrapure minivectors for gene therapy | Pending | 08-Sep-2022 | 000000000 | 00 |
| CA-3211300-A1 | Using minivectors to treat idiopathic pulmonary fibrosis | Pending | 07-Sep-2022 | 000000000 | |
| EP-4338755-A1 | Using minivectors to treat idiopathic pulmonary fibrosis | Pending | 07-Sep-2022 | 000000000 | 00 |
| US-20230190955-A1 | Treatment of liver cancer or liver fibrosis | Pending | 21-Oct-2021 | A61K48/0016 |
Velvet Therapeutics Executive Team (5)
| Name | Title | Board Seat |
|---|---|---|
| Lynn Zechiedrich Ph.D | Co-Founder, Chief Scientific Officer & Board Member | |
| Alex Steven | Executive Officer & Board Member | |
| Jamie Catanese Ph.D | Co-Founder & Scientific Advisor | |
| Christopher Coker | Chief Executive Officer, President & Board Member |
Velvet Therapeutics Board Members (5)
| Name | Representing | Role | Since |
|---|---|---|---|
| Alex Steven | Velvet Therapeutics | Executive Officer & Board Member | 000 0000 |
| Evan Davies | Self | Board Member | 000 0000 |
| Lynn Zechiedrich Ph.D | Velvet Therapeutics | Co-Founder, Chief Scientific Officer & Board Member | 000 0000 |
| Mark Matovich | Self | Board Member | 000 0000 |
| Michael Pavia Ph.D | Self | Board Member | 000 0000 |
Velvet Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Velvet Therapeutics Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| BCM Ventures | Venture Capital | Minority | 000 0000 | 000000 0 |
| Daniel Catanese | Angel (individual) | Minority | 000 0000 | 000000 0 |
| Jonathan Fogg | Angel (individual) | Minority | 000 0000 | 000000 0 |
Velvet Therapeutics FAQs
-
When was Velvet Therapeutics founded?
Velvet Therapeutics was founded in 2013.
-
Who is the founder of Velvet Therapeutics?
Lynn Zechiedrich Ph.D and Jamie Catanese Ph.D are the founders of Velvet Therapeutics.
-
Who is the CEO of Velvet Therapeutics?
Christopher Coker is the CEO of Velvet Therapeutics.
-
Where is Velvet Therapeutics headquartered?
Velvet Therapeutics is headquartered in Houston, TX.
-
What is the size of Velvet Therapeutics?
Velvet Therapeutics has 3 total employees.
-
What industry is Velvet Therapeutics in?
Velvet Therapeutics’s primary industry is Drug Discovery.
-
Is Velvet Therapeutics a private or public company?
Velvet Therapeutics is a Private company.
-
What is Velvet Therapeutics’s current revenue?
The current revenue for Velvet Therapeutics is 000000.
-
How much funding has Velvet Therapeutics raised over time?
Velvet Therapeutics has raised $1.12M.
-
Who are Velvet Therapeutics’s investors?
BCM Ventures, Daniel Catanese, and Jonathan Fogg have invested in Velvet Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
